Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in Peripheral Artery Disease
NCT06212271Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in peripheral artery disease (PAD) comparing Colchicine with Placebo (2 arms). Primary endpoint: Molecular imaging markers of inflammation at 4 weeks. Started Sep 2024; status: completed.
02
Drugs
colchicine
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT06212271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212271.